ArticlePLOS digital health2026
Heterogeneous associations of a mobile health-based disease management program on uncontrolled hypertension: A target trial emulation study.
Article in PLOS digital health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Long-term effectiveness of digital health interventions for hypertension remains unclear, particularly regarding individual variability in treatment response. This study examined the association of a mobile health-based disease management program for uncontrolled hypertension and assessed treatment effect heterogeneity using a target trial emulation framework. We analyzed health checkup data of employees June 2021-December 2023. Individuals with hypertension, diabetes, or dyslipidemia were invited to participate in a six-month mobile health-based disease management program incorporating lifestyle tracking via a mobile application and remote behavioral coaching. We compared the following two treatments using a target trial emulation framework: mobile health-based disease management program combined with conventional treatment, versus conventional treatment alone. The primary outcome was uncontrolled hypertension at the one-year follow-up (systolic ≥140 mmHg or diastolic ≥90 mmHg). We estimated average and individual treatment effects using outcome regression based on the G-formula with ensemble machine learning methods for model specification. Clustering analysis was used to identify heterogeneous subgroups and potential effect modifiers. Mobile health-based disease management program was associated with a 5.2% (95% confidence interval: 4.4% to 6.0%) lower prevalence of uncontrolled hypertension compared with conventional treatment. Treatment response varied, with greater benefits observed in individuals with a strong intention to improve lifestyle habits, higher diastolic blood pressure, and more favorable behavioral and metabolic characteristics. Age was associated with benefit, though it had relatively lower importance. Participation in a mobile health-based disease management program was associated with better blood pressure control over one year. The substantial variation in treatment effectiveness highlights the need for personalized digital health strategies.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.